- AuthorisedTherapeutic exploratory (Phase II)
COMPASS - COpenhagen MenoPAuSe Study
This study, called COMPASS, looks at how different treatments might help women going through menopause. Researchers want to understand how these treatments affect bones, hormones, and overall well-being like mood and sleep over 8 weeks.
For: MenopauseDenmark - AuthorisedTherapeutic confirmatory (Phase III)
Dehydroepiandrosterone (DHEA) as augmentation of standard antidepressants in treatment-resistant depression: a randomized controlled trial (DARE-Trial) - A multicenter, randomized, double-blind, placebo-controlled trial with group sequential design
This study is testing a new tablet called DHEA alongside usual antidepressant treatment for people with depression that hasn't improved with other treatments. Researchers want to see if DHEA helps reduce depression symptoms over six weeks and if it's safe to use.
For: Treatment Resistant Depression (TRD)Germany - Ongoing, recruitingPhase III and phase IV (Integrated)
Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients
This study looks at how well kidney transplant patients respond to COVID-19 and shingles vaccines when their anti-rejection medication is changed. It compares two different drug treatment plans to see which one helps the body make more protective antibodies.
For: kidney transplantation · COVID-19 · Herpes ZosterNetherlands - AuthorisedTherapeutic use (Phase IV)
A multi-center, open label, longitudinal, observational, 12-week study of Flexilev treatment with the dosing device OraFID and accompanying digital app in Parkinson patients.
This study looks at how people with Parkinson's disease use a device called OraFID and a special app to take their Flexilev medicine. It aims to understand how well they use it and how they feel about it over 12 weeks.
For: Parkinsons DiseaseSweden